Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 28, 2023
Daily News
December 28, 2023
- FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Japan Sets Up New Pharma Forum to Fight Drug Lag/Loss, Aims to Reflect Proposals in Honebuto
December 28, 2023
- Payers Reiterate Their Push for “1/2” LLP Copay Scenario for Price Gap from Generics
December 28, 2023
- Chuikyo Officially OKs Application of Elective Care for Off-Patent Branded Drugs
December 28, 2023
- Japan Maps Out Fresh 10-Year Strategy for Cancer Research
December 28, 2023
- South Korean Partner to Locally Manufacture Xocova: Shionogi
December 28, 2023
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…